Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction.
about
Abuse of amphetamines and structural abnormalities in the brainGenetics of Common Antipsychotic-Induced Adverse EffectsPharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genesTardive dyskinesia: therapeutic options for an increasingly common disorder.Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.Dopamine, affordance and active inference.Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophreniaA case of aripiprazole and tardive dyskinesia.The interaction of polymorphisms of IL10 and DBH was associated with general symptoms of PANSS with TD in Chinese Han schizophrenic patients.Association study indicates a protective role of phosphatidylinositol-4-phosphate-5-kinase against tardive dyskinesia.An update on tardive dyskinesia: from phenomenology to treatmentTreatment of Tardive Dyskinesia by tetrabenazine, clonazepam and vitamin E.Prolactin and psychopathology in schizophrenia: a literature review and reappraisalAdenosine A2A-receptor antagonism and pathophysiology of Parkinson's disease and drug-induced movement disorders.Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis.New insights into the mechanism of drug-induced dyskinesia.Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Pharmacogenetics of tardive dyskinesia: an updated review of the literature.Emerging pharmacological therapies in schizophrenia: what's new, what's different, what's next?Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy.Clozapine-induced Tardive DyskinesiaNMDA receptor genotypes associated with the vulnerability to develop dyskinesiaDo tardive dyskinesia and L-dopa induced dyskinesia share common genetic risk factors? An exploratory study.Effects of vitamin E supplementation on plasma membrane permeabilization and fluidization induced by chlorpromazine in the rat brain.Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Adjunctive use of interferon γ inducer for treatment of patients with schizophrenia.Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.Breakthrough drugs for the interface between psychiatry and neurology.Investigation of the Gene in Tardive Dyskinesia - New Data and Meta-Analysis
P2860
Q22241673-2746D515-2594-47BA-9072-C3E4EDD39804Q28072893-74D70DF5-A242-49FC-A522-336093A8D892Q28088705-B0D3935E-20E4-4423-A27D-0830B4EBB0D6Q30566749-43760944-E82F-4503-8834-45139ADA1024Q30747608-D6555274-4542-42C1-A444-DA8E395CD310Q34126224-1263A164-C07E-4DF3-85D8-00BBF7BDA6CCQ34642857-E5503A70-3EA9-4AF7-AA97-9907487AEF47Q34783260-A35ECE73-EE95-4099-9F9E-8AC26CB3E0D4Q34948226-E620B8C3-D7A0-4D13-90F0-05761F0174E2Q35626932-3D2065F0-86BA-43B8-ACA4-2761510925DFQ37006021-D0AFE07C-9249-42A3-B180-BE031B21F47AQ37370457-6D8192C8-CBD1-417E-833D-A996E552B241Q37700747-A8D73A54-555E-44D4-AA36-0267EB9445B5Q37963718-993EB02B-FD4A-40ED-A480-3B977379F9AAQ38032249-0F199C37-B8E2-42E8-B4B1-98DBDB574622Q38099662-512942EF-A008-4990-BCC2-98A5B074E561Q38789841-E8056A9C-6783-4BE5-B220-C01830CDBB61Q38911685-5CEF0010-13C6-4A77-92EF-EBB867AEC30AQ39065466-05A52C05-BD8D-4D8A-BE03-A9048A2109A8Q39396657-701C8E1A-2E34-4CA8-B0D2-EEDEFBF237EDQ41440274-AAA3E11B-F2DF-4669-AA57-FD36FD4B6F74Q42072420-04F7560F-8DFC-45D8-AF67-E3FAD91B0A75Q45007058-1EB05D8A-693A-4FB6-9F39-D44E7B9792E6Q46798703-768A014D-24EA-4BF8-A967-8AE7F7F0F177Q47675010-A1CB0DBE-16FB-4FF9-A6D7-B9D96D06707CQ47964432-1E483D52-B6A9-4BEC-9C61-5B725C9702ECQ54969812-3704AD4D-2F38-4655-9C17-57FDD8ADB9D5Q55059642-A691EB0C-EC69-49F3-BA49-CC83C2D7189CQ57073796-A1DC6665-252E-41F0-AB14-C98F92EB9622
P2860
Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Tardive dyskinesia in the era ...... y and mechanisms of induction.
@ast
Tardive dyskinesia in the era ...... y and mechanisms of induction.
@en
Tardive dyskinesia in the era ...... y and mechanisms of induction.
@nl
type
label
Tardive dyskinesia in the era ...... y and mechanisms of induction.
@ast
Tardive dyskinesia in the era ...... y and mechanisms of induction.
@en
Tardive dyskinesia in the era ...... y and mechanisms of induction.
@nl
prefLabel
Tardive dyskinesia in the era ...... y and mechanisms of induction.
@ast
Tardive dyskinesia in the era ...... y and mechanisms of induction.
@en
Tardive dyskinesia in the era ...... y and mechanisms of induction.
@nl
P2093
P2860
P1476
Tardive dyskinesia in the era ...... y and mechanisms of induction.
@en
P2093
Guy Chouinard
Howard C Margolese
Linda Beauclair
Robert Miller
Theodore T Kolivakis
P2860
P304
P356
10.1177/070674370505000907
P407
P577
2005-08-01T00:00:00Z